NCT07181538View on ClinicalTrials.gov

Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

February 20, 2025

Study Completion Date

March 5, 2025

Conditions
Healthy
Interventions
DRUG

JLP-2302

taking JLP-2302

DRUG

JP-1366

taking JP-1366

Trial Locations (1)

Unknown

Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Onconic Therapeutics Inc.

INDUSTRY

NCT07181538 - Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers | Biotech Hunter | Biotech Hunter